In patients with NSCLC (CheckMate 026) identified as PD-L1–positive by either AI-powered or manual scoring, progression-free survival was prolonged at a cutoff of ≥5% in patients treated with NIVO (Fig. 6B). This evidence concerns the gene CD274 and non-small cell lung carcinoma.